{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-020615","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2021-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.887793+00:00","generated_at":"2026-06-29T08:49:44.534019+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protagenic Therapeutics delays PT00114 trial start to Jan 2022; Q2 net loss $2.6M","bullets":["FDA required ready-to-inject vials; IND re-filing moved to Q4 2021, Phase I/IIa start to Jan 2022.","Q2 2021 net loss $2.6M (vs $0.6M in Q2 2020); G&A expense rose to $2.2M.","Closed $13.2M public offering of 3.18M units at $4.15/unit; cash $11.9M as of June 30, 2021.","Initial Phase I/IIa data readout expected 1H 2022, final readout Q3 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-020615","json":"https://secwatch.observer/filing/0001493152-21-020615.json","markdown":"https://secwatch.observer/filing/0001493152-21-020615.md","text":"https://secwatch.observer/filing/0001493152-21-020615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000149315221020615/0001493152-21-020615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000149315221020615/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T08:49:44.534019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}